Canton Strategic Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Canton Strategic Holdings Inc (CNTN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Canton Strategic Holdings Inc vs Its Competitors
- Profitability: Its -1,287.2% net margin compares with 18.8% for the peer group.
- Scale: Canton Strategic Holdings Inc ranks #191 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Canton Strategic Holdings Inc accounted for 0.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CNTN Sales vs. its Competitors, Q2 2026
With a net margin of -1,287.21 %, Canton Strategic Holdings Inc reported lower profitability than its competitors (18.75 %).
Canton Strategic Holdings Inc generated 0.01 % of the combined sales of its peer group.
Canton Strategic Holdings Inc vs. its Competitors, Q2 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Canton Strategic Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Canton Strategic Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Canton Strategic Holdings Inc's competitor groups requires a Commercial License.
Canton Strategic Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Canton Strategic Holdings Inc | - | - | - | - |
| Competitors combined (8) | ||||
| High-Confidence Competitors (3) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNTN Stock Performance relative to its Competitors
CNTN Stock Performance relative to High-Confidence Competitors
CNTN Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Moonlake Immunotherapeutics | 282.9% | Outperformed |
| 3 | Zymeworks Inc | 282.9% | Outperformed |
| 4 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Takeda Pharmaceutical Company Limited | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Canton Strategic Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Canton Strategic Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Canton Strategic Holdings Inc | 515.05 | - |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| Gsk Plc | 99,157.95 | 43,093.89 |
| Regeneron Pharmaceuticals Inc | 80,376.62 | 15,534.70 |
| Moderna Inc | 76,642.86 | 2,228.00 |
| Takeda Pharmaceutical Company Limited | 29,200.83 | 30,079.37 |
| SUBTOTAL | 751,979.32 | 155,359.08 |
Sign in to see all competitors of Canton Strategic Holdings Inc .
Sources: Canton Strategic Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Canton Strategic Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Canton Strategic Holdings Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Moderna Inc. | Named by the company | 85% |
| Bayer AG | Named by the company | 85% |
| Mirum Pharma | Named by the company | 85% |
| Ipsen Pharma | Named by the company | 85% |
| Roche/Genentech | Named by the company | 85% |
| BridgeBio Pharma, Inc. (Ferro Therapeutic, Inc.) | Named by the company | 85% |
| Kojin Therapeutics, Inc. | Named by the company | 85% |
| Cara Therapeutics | Named by the company | 85% |
| Moonlake Therapeutics | Named by the company | 85% |
| Abbvie Inc | Named by the company | 85% |
| Zymeworks Inc | Named by the company | 85% |
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| Regeneron Pharmaceuticals Inc | Named by the company | 85% |
| Tvardi Therapeutics Inc | Named by the company | 85% |
| Moonlake Immunotherapeutics | Named by the company | 85% |
| Gsk Plc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Canton Strategic Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Canton Strategic Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Canton Strategic Holdings Inc | 515 | - | - |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| Gsk Plc | 99,158 | 169,660,977 | 32,662,867 |
| Regeneron Pharmaceuticals Inc | 80,377 | 1,008,092 | 280,902 |
| Moderna Inc | 76,643 | 474,043 | -670,426 |
| Takeda Pharmaceutical Company Limited | 29,201 | 639,986 | 15,106 |
| PEERS TOTAL | 751,464 | 1,245,164 | 128,670 |
Sign in to see all peers for Canton Strategic Holdings Inc .
Canton Strategic Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Canton Strategic Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Canton Strategic Holdings Inc ranks #191 of 498 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 817, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,034,082 | 19.14 % |
| 2 | Johnson and Johnson | 645,992 | 11.96 % |
| 3 | Beone Medicines Ltd | 550,872 | 10.19 % |
| 4 | Abbvie Inc | 463,276 | 8.57 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 191 | Canton Strategic Holdings Inc | 515 | 0.01 % |
Market cap and industry share for the rest of Canton Strategic Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Canton Strategic Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 186 | Opus Genetics Inc | 539 | 178.77 % |
| 187 | Altimmune inc | 530 | -22.89 % |
| 188 | Evolus Inc | 527 | 29.56 % |
| 189 | Sagimet Biosciences inc | 525 | 38.44 % |
| 190 | Puma Biotechnology Inc | 1,234 | 12.3% |
| 191 | Canton Strategic Holdings Inc | 515 | -14.83 % |
| 192 | Arvinas Inc | 1,234 | 12.3% |
| 193 | Contineum Therapeutics Inc | 1,234 | 12.3% |
| 194 | Nuvectis Pharma inc | 1,234 | 12.3% |
| 195 | Kamada Ltd | 1,234 | 12.3% |
| 196 | Oculis Holding Ag | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Canton Strategic Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Canton Strategic Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 1.8x | 4.5x | -2.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -2.85 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Canton Strategic Holdings Inc's BCG Growth-Share Matrix
Relative market share (vs Canton Strategic Holdings Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Canton Strategic Holdings Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Canton Strategic Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 817 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Canton Strategic Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Canton Strategic Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Canton Strategic Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Canton Strategic Holdings Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Canton Strategic Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (37.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Canton Strategic Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Canton Strategic Holdings Inc | 11.44 | 12.72 | 0.00 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Takeda Pharmaceutical Company Limited | 0.15 | 1.01 | 0.58 |
Sign in to see all peers for Canton Strategic Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Canton Strategic Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Canton Strategic Holdings Inc | Q2 2026 | - | - |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Takeda Pharmaceutical Company Limited | Q1 2025 | +1.8 % | -28.9 % |
| PEERS TOTAL | +6.4 % | +108.8 % |
Sign in to see all peers for Canton Strategic Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Canton Strategic Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Canton Strategic Holdings Inc | Q2 2026 | - | - |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Takeda Pharmaceutical Company Limited | Q1 2025 | -8.7 % | +8.5 % |
Sign in to see all peers for Canton Strategic Holdings Inc .
Canton Strategic Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Canton Strategic Holdings Inc | - | - | - |
| Abbvie Inc | 4.68% | 9.11% | - |
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Moderna Inc | - | - | - |
| Takeda Pharmaceutical Company Limited | 0.75% | 0.97% | 1.53% |
Sign in to see all peers for Canton Strategic Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Canton Strategic Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Canton Strategic Holdings Inc | - | - |
| Abbvie Inc | 73.90 | 7.20 |
| Gsk Plc | 17.35 | 2.30 |
| Regeneron Pharmaceuticals Inc | 18.78 | 5.17 |
| Moderna Inc | - | 34.40 |
| Takeda Pharmaceutical Company Limited | 42.39 | 0.97 |
| PEERS AVERAGE | 46.84 | 4.84 |
Sign in to see all peers for Canton Strategic Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.